Loading company
Latest annual · FY2024
Millions- Total revenues
- 88
- Gross profit
- 73
- Operating income
- (31)
- Net income
- (30)
Latest quarter · Q2 FY2025
Millions- Total revenues
- 20
- Gross profit
- 17
- Operating income
- (6)
- Net income
- (3)
- Free cash flow
- 2
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +35.9%
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
Y-mAbs Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $87.7 million | $84.8 million | +3.4% | 10-K 2025-03-04 · proof |
| Gross profit | $72.7 million | $73.5 million | -1% | 10-K 2025-03-04 · proof |
| Operating income | -$31.2 million | -$25.7 million | 10-K 2025-03-04 · proof | |
| Net income | -$29.7 million | -$21.4 million | 10-K 2025-03-04 · proof | |
| Cash from operating activities | -$15.7 million | -$27.2 million | 10-K 2025-03-04 · proof | |
| Total assets | $119.9 million | $127.9 million | -6.2% | 10-K 2025-03-04 · proof |
| Total liabilities | $27.9 million | $26.9 million | +3.8% | 10-K 2025-03-04 · proof |
| Cash and cash equivalents | $67.2 million | $78.6 million | -14.5% | 10-K 2025-03-04 · proof |
- What was Y-mAbs Therapeutics, Inc.'s revenue in fiscal 2024?
- Y-mAbs Therapeutics, Inc. reported revenue of $87.7 million for fiscal 2024 (the year ended Dec 31, 2024), against $84.8 million the year before (+3.4%). Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What was Y-mAbs Therapeutics, Inc.'s gross profit in fiscal 2024?
- Y-mAbs Therapeutics, Inc. reported gross profit of $72.7 million for fiscal 2024 (the year ended Dec 31, 2024), against $73.5 million the year before (-1%). Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What was Y-mAbs Therapeutics, Inc.'s operating income in fiscal 2024?
- Y-mAbs Therapeutics, Inc. reported operating income of -$31.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$25.7 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What was Y-mAbs Therapeutics, Inc.'s net income in fiscal 2024?
- Y-mAbs Therapeutics, Inc. reported net income of -$29.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$21.4 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What was Y-mAbs Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Y-mAbs Therapeutics, Inc. reported cash from operating activities of -$15.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$27.2 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What are Y-mAbs Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Y-mAbs Therapeutics, Inc. reported total assets of $119.9 million, against $127.9 million a year earlier (-6.2%). Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What are Y-mAbs Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Y-mAbs Therapeutics, Inc. reported total liabilities of $27.9 million, against $26.9 million a year earlier (+3.8%). Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
- What are Y-mAbs Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Y-mAbs Therapeutics, Inc. reported cash and cash equivalents of $67.2 million, against $78.6 million a year earlier (-14.5%). Source: the 10-K filed with the SEC on Mar 4, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1722964&period_type=annual&limit=5"Information only, not investment advice.